Eli Lilly Aktie
WKN: 858560 / ISIN: US5324571083
|
21.10.2025 11:00:00
|
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, was a pioneer in the GLP-1 market. The pharmaceutical giant launched medicines like Ozempic and Wegovy, which became hugely famous and successful brand names.However, Novo Nordisk has been rapidly losing its lead in this area to Eli Lilly (NYSE: LLY), a company with which it's battled in the market for diabetes medicines for decades. Lilly is still recording wins and recently made some clinical progress with a candidate that could grant it an even bigger edge over its competitor. Here's what investors need to know.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Eli Lilly
Analysen zu Eli Lilly
| 04.02.26 | Eli Lilly Buy | Goldman Sachs Group Inc. | |
| 20.12.24 | Eli Lilly Buy | Jefferies & Company Inc. | |
| 31.10.24 | Eli Lilly Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
| Eli Lilly | 1 063,40 | 7,35% |
|